CAROLINE BLOSS: Open Payments
NPI 1003582008 · PHILADELPHIA, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$747 in 34 payments from 13 companies in 2025. Trend: 2023 $1,797 · 2024 $1,814 · 2025 $747
Food & beverage: $747
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 7 | $162 |
| GlaxoSmithKline, LLC. | 4 | $103 |
| AstraZeneca Pharmaceuticals LP | 5 | $90 |
| Lilly USA, LLC | 3 | $78 |
| SHIELD THERAPEUTICS INC | 1 | $54 |
| Astellas Pharma US Inc | 2 | $47 |
| PFIZER INC. | 2 | $44 |
| Novo Nordisk Inc | 2 | $40 |
| Kowa Pharmaceuticals America, Inc. | 2 | $35 |
| Phathom Pharmaceuticals, Inc. | 2 | $29 |
Products named: VRAYLAR, TRELEGY ELLIPTA, ACCRUFER, MOUNJARO, Veozah, FARXIGA, ZORYVE, VOQUEZNA.
Industry payments across PA — which companies pay providers there.
